Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
63
SURI Quote, Financials, Valuation and Earnings
Last price:
$17.90
Seasonality move
:
-8.84%
Day range:
$17.86 - $17.91
52-week range:
$12.71 - $18.70
Dividend yield:
15.19%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
873
Avg. volume:
3K
1-year change:
-2.47%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
LFSC
F/m Emerald Life Sciences Innovation ETF
|
-- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
$17.91 | -- | -- | -- | $0.68 | 15.19% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$38.19 | -- | -- | -- | $0.24 | 0.63% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$79.36 | -- | -- | -- | $0.00 | 0% | -- |
|
LFSC
F/m Emerald Life Sciences Innovation ETF
|
$37.91 | -- | -- | -- | $0.00 | 0% | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
$50.15 | -- | -- | -- | $1.17 | 2.34% | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
$54.29 | -- | -- | -- | $0.10 | 0.93% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | 1.924 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.813 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.818 | -- | -- |
|
LFSC
F/m Emerald Life Sciences Innovation ETF
|
-- | 1.835 | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | 1.453 | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | 0.588 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
LFSC
F/m Emerald Life Sciences Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Simplify Propel Opportunities ETF vs. Competitors
-
Which has Higher Returns SURI or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About SURI or BBC?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is SURI or BBC More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, suggesting its less volatile than the S&P 500 by 1.702%.
-
Which is a Better Dividend Stock SURI or BBC?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 15.19%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 0.63% to investors and pays a quarterly dividend of $0.24 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or BBC?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns SURI or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About SURI or BBP?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is SURI or BBP More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.974%.
-
Which is a Better Dividend Stock SURI or BBP?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 15.19%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or BBP?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns SURI or LFSC?
F/m Emerald Life Sciences Innovation ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat F/m Emerald Life Sciences Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- LFSCF/m Emerald Life Sciences Innovation ETF-- -- -- -
What do Analysts Say About SURI or LFSC?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand F/m Emerald Life Sciences Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than F/m Emerald Life Sciences Innovation ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than F/m Emerald Life Sciences Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 LFSCF/m Emerald Life Sciences Innovation ETF0 0 0 -
Is SURI or LFSC More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison F/m Emerald Life Sciences Innovation ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SURI or LFSC?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 15.19%. F/m Emerald Life Sciences Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. F/m Emerald Life Sciences Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or LFSC?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than F/m Emerald Life Sciences Innovation ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than F/m Emerald Life Sciences Innovation ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while F/m Emerald Life Sciences Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for F/m Emerald Life Sciences Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- LFSCF/m Emerald Life Sciences Innovation ETF-- -- -- --
-
Which has Higher Returns SURI or SBIO?
ALPS Medical Breakthroughs ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat ALPS Medical Breakthroughs ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- -
What do Analysts Say About SURI or SBIO?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ALPS Medical Breakthroughs ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than ALPS Medical Breakthroughs ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than ALPS Medical Breakthroughs ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 SBIOALPS Medical Breakthroughs ETF0 0 0 -
Is SURI or SBIO More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ALPS Medical Breakthroughs ETF has a beta of 0.849, suggesting its less volatile than the S&P 500 by 15.057%.
-
Which is a Better Dividend Stock SURI or SBIO?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 15.19%. ALPS Medical Breakthroughs ETF offers a yield of 2.34% to investors and pays a quarterly dividend of $1.17 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. ALPS Medical Breakthroughs ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or SBIO?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than ALPS Medical Breakthroughs ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than ALPS Medical Breakthroughs ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while ALPS Medical Breakthroughs ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for ALPS Medical Breakthroughs ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- --
-
Which has Higher Returns SURI or XPH?
State Street SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat State Street SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About SURI or XPH?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than State Street SPDR S&P Pharmaceuticals ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than State Street SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 -
Is SURI or XPH More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.268%.
-
Which is a Better Dividend Stock SURI or XPH?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 15.19%. State Street SPDR S&P Pharmaceuticals ETF offers a yield of 0.93% to investors and pays a quarterly dividend of $0.10 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. State Street SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or XPH?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than State Street SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while State Street SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for State Street SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.06% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2.97% over the past day.
